Dr. Zhang on adaptive phase 3 trial of nivolumab, ipilimumab, and cabozantinib in kidney cancer

Video

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE study (NCT03793166) exploring immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) followed by nivolumab or nivolumab with cabozantinib (Cabometyx) for patients with intermediate/poor-risk metastatic clear cell renal cell carcinoma

Zhang, who is an associate professor at UT Southwestern Medical Center, was interviewed during the 2021 Kidney cancer research summit in Philadelphia, Pennsylvania.

Related Videos
Dr. Neal E. Rowe in an interview with Urology Times
Carlos Muñoz-Lopez and Dr. Steven Campbell in an interview with Urology Times
Carlos Muñoz-Lopez and Dr. Steven Campbell in an interview with Urology Times
Dr. Michael Stifelman in an interview with Urology Times
Teona Iarajuli in an interview with Urology Times
hospital corridor
Andrew Wood, MD, answers a question during a Zoom interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.